Pfizer delivered better-than-expected second-quarter results on Tuesday, but the headline for investors was the company's decision to deepen its cost-cutting program by another $2.5 billion. The move underscores how the drugmaker is working to replace the revenue it once earned from its COVID-19 products.
The company said it now targets $9.7 billion in net savings through 2029, up from a previous goal of $7.2 billion. That's a significant escalation in its efficiency drive, and it reflects the reality that COVID-related sales are unlikely to return to their pandemic-era peaks.
What's driving the quarter
Pfizer's second-quarter performance was buoyed by its established blockbusters and newer oncology drugs. The blood thinner Eliquis, which Pfizer markets in partnership with Bristol Myers Squibb, saw sales jump about 21% to $2.43 billion. Meanwhile, the cancer drug Padcev rose 23% to $667 million. These gains helped offset the continued slide in COVID product sales, which have been falling as global demand for vaccines and treatments normalizes.
The results echo a broader trend in the pharmaceutical sector, where companies that saw a pandemic-era windfall are now having to pivot. For Pfizer, that means leaning on its core portfolio while trimming costs to protect margins. The company's ability to beat expectations despite the COVID drag suggests its non-COVID business is holding up well.
Why the cost cuts matter
Cost-cutting programs of this scale are not just about trimming fat. They often involve streamlining manufacturing, consolidating research sites, and reducing headcount. For a company of Pfizer's size, $9.7 billion in net savings is a substantial sum that could help support earnings per share even as revenue growth slows.
Investors tend to view such programs positively, as they signal management's commitment to protecting profitability. However, they also raise questions about whether the company can maintain its innovation pipeline while cutting costs. Pfizer has been active in M&A, including its recent deal to buy supplement maker Thorne, and it will need to balance efficiency with investment in future growth.
What it means for investors
For everyday investors, the key takeaway is that Pfizer is in a transition phase. The days of massive COVID-driven revenue are over, and the company is now focused on building a more sustainable business. The strong performance of Eliquis and Padcev is encouraging, but the continued decline in COVID sales is a reminder that no product line lasts forever.
The increased cost-cutting target suggests management is serious about protecting the bottom line. That could be a positive for shareholders, as it may help support the dividend and share buybacks. However, it also means the company is expecting a longer period of pressure on its top line.
Pfizer's results come amid a broader earnings season where stocks have edged up on strong corporate results. The market's reaction to Pfizer's news will be closely watched, as investors weigh the beat against the deeper cuts.
Looking ahead, investors will likely focus on how Pfizer plans to deploy its savings. Will it invest in new drugs, make more acquisitions, or return cash to shareholders? The company's ability to execute its strategy will be key to its long-term performance.
For now, the message from Pfizer is clear: it's adapting to a post-COVID world, and it's willing to make tough choices to ensure its financial health. That's a story many investors can understand, even if the details are complex.
